Literature DB >> 34424045

Case Commentary: Uncertainty in Evaluating Treatment Outcomes in Carbapenem-Resistant Acinetobacter baumannii Infections.

Jessica Howard-Anderson1, David van Duin2.   

Abstract

Carbapenem-resistant Acinetobacter baumannii (CRAB) infections are challenging to treat and associated with poor clinical outcomes. In this issue, sulbactam-durlobactam, a novel β-lactam-β-lactamase inhibitor, was used with cefiderocol to successfully treat CRAB pneumonia. While this report and in vitro data are encouraging, determining the impact of treatment regimens on clinical outcomes after CRAB infections is not straightforward. Therefore, careful evaluation in pathogen-directed randomized controlled trials is needed to determine the optimal treatment of CRAB infections.

Entities:  

Keywords:  Acinetobacter; cefiderocol; durlobactam; sulbactam

Mesh：

Substances：

Year:  2021        PMID： 34424045      PMCID： PMC8522720          DOI： 10.1128/AAC.01424-21

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  17 in total

1.  In Vitro Activity of Sulbactam-Durlobactam against Acinetobacter baumannii-calcoaceticus Complex Isolates Collected Globally in 2016 and 2017.

Authors:  Sarah M McLeod; Samir H Moussa; Meredith A Hackel; Alita A Miller
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

Review 2.  Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges.

Authors:  Darren Wong; Travis B Nielsen; Robert A Bonomo; Paul Pantapalangkoor; Brian Luna; Brad Spellberg
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

Review 3.  New Treatment Options against Carbapenem-Resistant Acinetobacter baumannii Infections.

Authors:  Burcu Isler; Yohei Doi; Robert A Bonomo; David L Paterson
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

4.  Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial.

Authors:  Mical Paul; George L Daikos; Emanuele Durante-Mangoni; Dafna Yahav; Yehuda Carmeli; Yael Dishon Benattar; Anna Skiada; Roberto Andini; Noa Eliakim-Raz; Amir Nutman; Oren Zusman; Anastasia Antoniadou; Pia Clara Pafundi; Amos Adler; Yaakov Dickstein; Ioannis Pavleas; Rosa Zampino; Vered Daitch; Roni Bitterman; Hiba Zayyad; Fidi Koppel; Inbar Levi; Tanya Babich; Lena E Friberg; Johan W Mouton; Ursula Theuretzbacher; Leonard Leibovici
Journal:  Lancet Infect Dis       Date:  2018-02-16       Impact factor: 25.071

5.  Prevalence and Molecular Characterization of New Delhi Metallo-Beta-Lactamases in Multidrug-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii from India.

Authors:  Mohibur Rahman; Kashi Nath Prasad; Shefali Gupta; Sanjay Singh; Avinash Singh; Ashutosh Pathak; Kamlesh Kumar Gupta; Saheem Ahmad; Bruno Gonzalez-Zorn
Journal:  Microb Drug Resist       Date:  2017-10-23       Impact factor: 3.431

6.  In vitro activity of sulbactam/durlobactam against global isolates of carbapenem-resistant Acinetobacter baumannii.

Authors:  Harald Seifert; Carina Müller; Danuta Stefanik; Paul G Higgins; Alita Miller; Michael Kresken
Journal:  J Antimicrob Chemother       Date:  2020-09-01       Impact factor: 5.790

7.  A Four-Biomarker Blood Signature Discriminates Systemic Inflammation Due to Viral Infection Versus Other Etiologies.

Authors:  D L Sampson; B A Fox; T D Yager; S Bhide; S Cermelli; L C McHugh; T A Seldon; R A Brandon; E Sullivan; J J Zimmerman; M Noursadeghi; R B Brandon
Journal:  Sci Rep       Date:  2017-06-06       Impact factor: 4.379

8.  Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.

Authors:  Matteo Bassetti; Roger Echols; Yuko Matsunaga; Mari Ariyasu; Yohei Doi; Ricard Ferrer; Thomas P Lodise; Thierry Naas; Yoshihito Niki; David L Paterson; Simon Portsmouth; Julian Torre-Cisneros; Kiichiro Toyoizumi; Richard G Wunderink; Tsutae D Nagata
Journal:  Lancet Infect Dis       Date:  2020-10-12       Impact factor: 71.421

Review 9.  Durlobactam, a New Diazabicyclooctane β-Lactamase Inhibitor for the Treatment of Acinetobacter Infections in Combination With Sulbactam.

Authors:  Adam B Shapiro; Samir H Moussa; Sarah M McLeod; Thomas Durand-Réville; Alita A Miller
Journal:  Front Microbiol       Date:  2021-07-19       Impact factor: 5.640

Review 10.  Treatment of patients with serious infections due to carbapenem-resistant Acinetobacter baumannii: How viable are the current options?

Authors:  J Nicholas O'Donnell; Vibert Putra; Thomas P Lodise
Journal:  Pharmacotherapy       Date:  2021-07-22       Impact factor: 4.705
View more
  1 in total

1.  Assessment of sustained efficacy and resistance emergence under human-simulated exposure of cefiderocol against Acinetobacter baumannii using in vitro chemostat and in vivo murine infection models.

Authors:  Christian M Gill; Kamilia Abdelraouf; Merime Oota; Rio Nakamura; Miho Kuroiwa; Yoshino Ishioka; Miki Takemura; Yoshinori Yamano; David P Nicolau
Journal:  JAC Antimicrob Resist       Date:  2022-05-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.